Prognostic and Predictive Potential of CCL5 Expression in Muscle-Invasive Bladder Cancer Patients.
CCL5
chemokine
chemotherapy
immune cells
muscle-invasive bladder cancer
prognosis
tumor cells
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
07 Jun 2024
07 Jun 2024
Historique:
received:
10
04
2024
revised:
31
05
2024
accepted:
04
06
2024
medline:
27
6
2024
pubmed:
27
6
2024
entrez:
27
6
2024
Statut:
epublish
Résumé
Bladder cancer (BC) is the 12th most commonly diagnosed cancer worldwide. Although there are several well-established molecular and immunological classifications, prognostic and predictive markers for tumor cells and immune cells are still needed. Using a tissue microarray, we analyzed the expression of the chemokine CC motif ligand 5 (CCL5) by immunohistochemistry (IHC) in 175 muscle-invasive BC samples. The application of a single cutoff for the staining status of tumor cells (TCs; positive vs. negative) and immune cells (ICs; positive vs. negative) revealed 75 patients (42.9%) and 123 patients (70.3%) with CCL5-positive TCs or ICs, respectively. IHC results were associated with prognostic and predictive data. Multivariate Cox regression analysis revealed that positive CCL5 staining in TCs was associated with significantly shorter disease-specific survival (DSS; RR = 1.51;
Identifiants
pubmed: 38928033
pii: ijms25126325
doi: 10.3390/ijms25126325
pii:
doi:
Substances chimiques
Chemokine CCL5
0
Biomarkers, Tumor
0
CCL5 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Rudolf und Irmgard Kleinknecht-Stiftung
ID : none
Organisme : Johannes und Frieda Marohn-Stiftung
ID : none
Organisme : Wilhelm Sander-Stiftung
ID : none
Organisme : Deutsche Forschungsgemeinschaft
ID : TA 145/17-1